New combo therapy aims to shrink Hard-to-Treat skin lymphoma
NCT ID NCT05956041
First seen Dec 30, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or eliminate advanced cutaneous T-cell lymphoma that has come back or not responded to prior treatment. About 23 adults with stage IIB-IVB disease will receive the drugs in 6-week cycles for up to 2 years. The main goal is to see how many patients achieve a complete response at 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.